B. Freilich

4.5k total citations · 1 hit paper
33 papers, 1.1k citations indexed

About

B. Freilich is a scholar working on Hepatology, Epidemiology and Rheumatology. According to data from OpenAlex, B. Freilich has authored 33 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hepatology, 18 papers in Epidemiology and 6 papers in Rheumatology. Recurrent topics in B. Freilich's work include Hepatitis C virus research (16 papers), Liver Disease Diagnosis and Treatment (11 papers) and Hepatitis B Virus Studies (6 papers). B. Freilich is often cited by papers focused on Hepatitis C virus research (16 papers), Liver Disease Diagnosis and Treatment (11 papers) and Hepatitis B Virus Studies (6 papers). B. Freilich collaborates with scholars based in United States, France and United Kingdom. B. Freilich's co-authors include Stephen A. Harrison, Chen Hu, Erica Fong, Guy Neff, Andrew Cheng, Cynthia Behling, Peter Ruane, Rashmee Patil, Tim Rolph and Brittany de Temple and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

B. Freilich

29 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

2021 255 citations Stephen A. Harrison, Peter Ruane et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
B. Freilich United States	13	760	467	303	241	98	33	1.1k
Ning‐Ping Zhang China	13	495 0.7×	337 0.7×	215 0.7×	45 0.2×	59 0.6×	28	768
Tomoko Tadokoro Japan	20	286 0.4×	224 0.5×	400 1.3×	77 0.3×	90 0.9×	74	933
Hajime Sunagozaka Japan	20	401 0.5×	457 1.0×	296 1.0×	131 0.5×	196 2.0×	42	1.1k
Takeo Miyahara Japan	8	488 0.6×	486 1.0×	228 0.8×	38 0.2×	157 1.6×	11	927
Mohamed Shoreibah United States	13	414 0.5×	363 0.8×	251 0.8×	51 0.2×	91 0.9×	54	779
Po‐Lin Tseng Taiwan	22	884 1.2×	869 1.9×	174 0.6×	40 0.2×	54 0.6×	57	1.2k
Satoshi Shakado Japan	13	257 0.3×	267 0.6×	109 0.4×	36 0.1×	131 1.3×	84	571
Ewa Gruszewska Poland	13	199 0.3×	141 0.3×	167 0.6×	34 0.1×	71 0.7×	50	505
Masaya Shigeno Japan	9	278 0.4×	287 0.6×	168 0.6×	39 0.2×	51 0.5×	13	599
Jue Wei China	17	272 0.4×	181 0.4×	487 1.6×	25 0.1×	94 1.0×	30	934

Countries citing papers authored by B. Freilich

Since Specialization

Citations

This map shows the geographic impact of B. Freilich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Freilich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Freilich more than expected).

Fields of papers citing papers by B. Freilich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Freilich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Freilich. The network helps show where B. Freilich may publish in the future.

Co-authorship network of co-authors of B. Freilich

This figure shows the co-authorship network connecting the top 25 collaborators of B. Freilich. A scholar is included among the top collaborators of B. Freilich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Freilich. B. Freilich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rinella, Mary E., Hsiao D. Lieu, Kris V. Kowdley, et al.. (2023). A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis. Hepatology. 79(3). 674–689. 62 indexed citations

Harrison, Stephen A., Peter Ruane, B. Freilich, et al.. (2022). A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. JHEP Reports. 5(1). 100563–100563. 72 indexed citations

Harrison, Stephen A., Peter Ruane, B. Freilich, et al.. (2021). Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. Nature Medicine. 27(7). 1262–1271. 255 indexed citations breakdown →

Shiffman, Mitchell L., B. Freilich, Raj Vuppalanchi, et al.. (2019). Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non‐alcoholic fatty liver disease. Publisher.

Shiffman, Mitchell L., B. Freilich, Raj Vuppalanchi, et al.. (2018). Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non‐alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics. 49(1). 64–73. 88 indexed citations

Rodríguez‐Torres, M., John M. Hill, B. Freilich, et al.. (2016). GS‐9857 in patients with chronic hepatitis C virus genotype 1–4 infection: a randomized, double‐blind, dose‐ranging phase 1 study. Journal of Viral Hepatitis. 23(8). 614–622. 40 indexed citations

Abou-Alfa, G.K., Jonghun Yoon, Manuel Modiano, et al.. (2016). An open-label, multi-center, phase I/II, dose escalation study of IV TKM-080301 in subjects with advanced hepatocellular carcinoma. European Journal of Cancer. 69. S22–S22. 3 indexed citations

Nelson, David R., Daniel Bernstein, B. Freilich, et al.. (2015). P0782 : All-oral 12-week combination treatment with daclatasvir (DCV) and sofosbuvir (SOF) in treatment-experienced patients infected with HCV genotype (GT) 3: A subanalysis of the ALLY-3 phase 3 study. Journal of Hepatology. 62. S624–S624. 9 indexed citations

Lawitz, Eric, William O’Riordan, Armen Asatryan, et al.. (2015). Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection. Antimicrobial Agents and Chemotherapy. 60(3). 1546–1555. 40 indexed citations

10.

Rodríguez‐Torres, M., John M. Hill, B. Freilich, et al.. (2015). P0901 : The pan-genotypic NS3/4A protease inhibitor GS-9857 demonstrates potent antiviral activity in patients infected with HCV genotype 1, 2, 3 or 4 in a 3-day monotherapy study. Journal of Hepatology. 62. S682–S682. 3 indexed citations

11.

Shiffman, Mitchell L., B. Freilich, Raj Vuppalanchi, et al.. (2015). LP37 : A placebo-controlled, multicenter, double-blind, randomised trial of emricasan in subjects with non-alcoholic fatty liver disease (NAFLD) and raised transaminases. Journal of Hepatology. 62. S282–S282. 27 indexed citations

12.

Lalezari, Jacob, E. Läwitz, M. Rodríguez‐Torres, et al.. (2011). 61 ONCE DAILY PSI-7977 PLUS PEGIFN/RBV IN A PHASE 2B TRIAL: RAPID VIROLOGIC SUPPRESSION IN TREATMENT-NAIVE PATIENTS WITH HCV GT2/GT3. Journal of Hepatology. 54. S28–S28. 37 indexed citations

13.

Jensen, Dorte Møller, Antonio Craxı̀, Carlos Eduardo Brandão‐Mello, et al.. (2009). 620 IDENTIFYING PATIENTS WITH A HIGH LIKELIHOOD OF ACHIEVING AN SVR FOLLOWING RE-TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN: USE OF POSITIVE PROGNOSTIC FACTORS (PPF'S). Journal of Hepatology. 50. S228–S228. 1 indexed citations

14.

Marcellin, Patrick, B. Freilich, Pietro Andreoné, et al.. (2008). S1938 HCV-RNA Status At Week 12 of Treatment with Peginterferon Alfa-2a/RBV Predicts SVR in Patients with Prior Non-Response to Pegylated Interferon Alfa-2b/RBV: Results from Repeat Study. Gastroenterology. 134(4). A–788.

15.

Afdhal, Nezam H., R Levine, R. Brown, et al.. (2008). 3 COLCHICINE VERSUS PEG-INTERFERON ALFA 2B LONG TERM THERAPY: RESULTS OF THE 4 YEAR COPILOT TRIAL. Journal of Hepatology. 48. S4–S4. 56 indexed citations

16.

Jensen, Dorte Møller, B. Freilich, Pietro Andreoné, et al.. (2008). 797 EASY TO ASSESS ON-TREATMENT PARAMETERS CORRELATE WITH DEGREE OF VIROLOGICAL RESPONSE AFTER 12 WEEKS OF TREATMENT. Journal of Hepatology. 48. S297–S298. 2 indexed citations

17.

Ghalib, R., E. Läwitz, B. Freilich, et al.. (2007). [649] CPG 10101 (ACTILON) IN COMBINATION WITH PEGYLATED INTERFERON AND/OR RIBAVIRIN IN CHRONIC HCV GENOTYPE 1 INFECTED PATIENTS WITH PRIOR RELAPSED RESPONSE: WEEK 48 DATA. Journal of Hepatology. 46. S245–S246. 7 indexed citations

18.

Marcellin, Patrick, G Teuber, V. Canva, et al.. (2006). 11 Efficacy of standard-dose and fixed-dose induction peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) among pegylated interferon alpha-2b (12kd)/ribavirin non-responders: Interim analysis of the repeat study. Journal of Hepatology. 44. S7–S7. 4 indexed citations

19.

Jacobson, Ira M., Nezam H. Afdhal, B. Freilich, et al.. (2006). 41 Differences in treatment outcome to antiviral therapy based on genotype and viral load in hepatitis C genotypes 2 and 3 in the Win-R trial. Journal of Hepatology. 44. S20–S20. 12 indexed citations

20.

Freilich, B. & C N Bernstein. (1995). Vasculitis possibly confined to the small and large intestine.. PubMed. 162(1). 63–5. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact